Xuetao Shi

机构：China Three Gorges Corporation (China), China Three Gorges University, Shandong Tumor Hospital, Shandong First Medical University

发表论文 34 篇 · 总被引 1909 次 · h-index 10

代表论文

• Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study (2021 · The Lancet Oncology · 被引 1136)
• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 513)
• Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial (2025 · ˜The œLancet. Gastroenterology & hepatology · 被引 45)
• Visual impairment and blindness caused by retinal diseases: A nationwide register-based study (2023 · Journal of Global Health · 被引 44)
• Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer (2017 · Clinical Infectious Diseases · 被引 24)
• Restoring periodontal tissue homoeostasis prevents cognitive decline by reducing the number of Serpina3nhigh astrocytes in the hippocampus (2023 · The Innovation · 被引 22)